Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mevacor OTC Actual-Use Study Data May Answer Future NDAC Questions

This article was originally published in The Tan Sheet

Executive Summary

Nearly half of high-risk patients in the Mevacor OTC actual-use study took the low-dose statin only after securing approval from a doctor, writes Eric Brass, MD/PhD, UCLA Medical Center, in a supplement to the Nov. 15 American Journal of Cardiology
Advertisement

Related Content

Healthcare Payers Split On Promoting OTC Statin Use – Survey
OTC Mevacor CUSTOM Label Illustrates New Approach Toward Approval
OTC Mevacor CUSTOM Label Illustrates New Approach Toward Approval
Healthcare Payers Split On Promoting OTC Statin Use – Survey
OTC Mevacor CUSTOM Label Illustrates New Approach Toward Approval
Healthcare Payers Split On Promoting OTC Statin Use – Survey
NDAC/Endocrinologic Drug Joint Panel Meeting Likely To Focus On Statins
Experts Weigh In On Zocor “Pharmacy Status” In UK, Prospects For U.S. Statin Switch
Mevacor Study Comparing Rx, OTC Use Is Among FDA Panel Suggestions
Mevacor Study Comparing Rx, OTC Use Is Among FDA Panel Suggestions

Topics

Advertisement
UsernamePublicRestriction

Register

PS097521

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel